H. Alheid

Papers

1

Total Citations

152

H-Index

1

About

Dr. H. Alheid is a leading figure in radiation oncology, whose work has fundamentally advanced the clinical application of stereotactic body radiotherapy (SBRT) for metastatic disease. Their primary research focuses on optimizing SBRT for oligometastases, particularly within the liver and lung, and establishing large-scale, real-world evidence to guide treatment patterns. Dr. Alheid’s most significant contribution is spearheading the German Society for Radiation Oncology (DEGRO) SBRT database initiative. This landmark project, detailed in their most-cited paper (152 citations), analyzed outcomes for 474 patients with 623 liver oligometastases, providing crucial insights into factors influencing local control and overall survival. This work has become a cornerstone for defining standards of care in the field. By aggregating multi-institutional data, Dr. Alheid has enabled robust, evidence-based analysis of SBRT efficacy, directly shaping clinical practice and patient selection. Their research continues to have a profound impact, offering a clear, data-driven roadmap for the safe and effective use of high-precision radiotherapy in the management of limited metastatic cancer.

Research Focus

Key Achievements

1
H-Index
1
Papers
152
Total Citations
152
Avg Citations/Paper
🏆 Most Cited Paper
The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases
152 citations · 2018
📈 Most Prolific Year: 2018 (1 Papers)
🤝 Key Collaborators: 19

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago